KMTS (Kestra Medical Technologies) Piotroski F-Score: N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
10 GF Score
Price $24.24
! 4 Warning Signs
View Full Analysis

What is Kestra Medical Technologies Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Kestra Medical Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Kestra Medical Technologies's Piotroski F-Score or its related term are showing as below:

During the past 4 years, the highest Piotroski F-Score of Kestra Medical Technologies was 7. The lowest was 5. And the median was 5.

Kestra Medical Technologies  (NAS:KMTS) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Kestra Medical Technologies Piotroski F-Score Related Terms


Kestra Medical Technologies Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies Piotroski F-Score Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24
Piotroski F-Score
N/A N/A N/A N/A

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 5.00 N/A 5.00 N/A

KMTS vs ATRC, STAA, BLFS: Piotroski F-Score Comparison

For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kestra Medical Technologies Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Kestra Medical Technologies's Piotroski F-Score falls into.


KMTS
10GF Score
Kestra Medical Technologies Ltd KMTS
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jan26) TTM:Last Year (Jan25) TTM:
Net Income was -52.053 + -25.826 + -32.785 + -34.166 = $-144.83 Mil.
Cash Flow from Operations was -24.056 + -26.274 + -18.343 + -18.366 = $-87.04 Mil.
Revenue was 17.233 + 19.371 + 22.565 + 24.552 = $83.72 Mil.
Gross Profit was 7.633 + 8.851 + 11.424 + 12.906 = $40.81 Mil.
Average Total Assets from the begining of this year (Jan25)
to the end of this year (Jan26) was
(107.995 + 295.744 + 266.296 + 246.701 + 379.342) / 5 = $259.2156 Mil.
Total Assets at the begining of this year (Jan25) was $108.00 Mil.
Long-Term Debt & Capital Lease Obligation was $46.54 Mil.
Total Current Assets was $314.06 Mil.
Total Current Liabilities was $42.93 Mil.
Net Income was -22.284 + -19.884 + -20.368 + -21.509 = $-84.05 Mil.

Revenue was 10.054 + 12.782 + 14.71 + 15.09 = $52.64 Mil.
Gross Profit was 1.397 + 4.2 + 5.83 + 6.547 = $17.97 Mil.
Average Total Assets from the begining of last year (Jan24)
to the end of last year (Jan25) was
(0 + 45.949 + 0 + 121.454 + 107.995) / 5 = $91.79933333 Mil.
Total Assets at the begining of last year (Jan24) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $46.61 Mil.
Total Current Assets was $69.92 Mil.
Total Current Liabilities was $38.69 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Kestra Medical Technologies's current Net Income (TTM) was -144.83. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Kestra Medical Technologies's current Cash Flow from Operations (TTM) was -87.04. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jan25)
=-144.83/107.995
=-1.34108061

ROA (Last Year)=Net Income/Total Assets (Jan24)
=-84.045/0
=

Kestra Medical Technologies's return on assets of this year was -1.34108061. Kestra Medical Technologies's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Kestra Medical Technologies's current Net Income (TTM) was -144.83. Kestra Medical Technologies's current Cash Flow from Operations (TTM) was -87.04. ==> -87.04 > -144.83 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jan26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan25 to Jan26
=46.537/259.2156
=0.17953009

Gearing (Last Year: Jan25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jan24 to Jan25
=46.611/91.79933333
=0.50774879

Kestra Medical Technologies's gearing of this year was 0.17953009. Kestra Medical Technologies's gearing of last year was 0.50774879. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jan26)=Total Current Assets/Total Current Liabilities
=314.063/42.931
=7.31552957

Current Ratio (Last Year: Jan25)=Total Current Assets/Total Current Liabilities
=69.916/38.693
=1.80694182

Kestra Medical Technologies's current ratio of this year was 7.31552957. Kestra Medical Technologies's current ratio of last year was 1.80694182. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Kestra Medical Technologies's number of shares in issue this year was 55.848. Kestra Medical Technologies's number of shares in issue last year was 49.534. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=40.814/83.721
=0.48750015

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=17.974/52.636
=0.34147732

Kestra Medical Technologies's gross margin of this year was 0.48750015. Kestra Medical Technologies's gross margin of last year was 0.34147732. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jan25)
=83.721/107.995
=0.77523033

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jan24)
=52.636/0
=

Kestra Medical Technologies's asset turnover of this year was 0.77523033. Kestra Medical Technologies's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+1+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Kestra Medical Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.


Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score

Get the complete analysis for KMTS

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.24
Price